Our research includes three broad domains: 1) understanding the genetic and environmental determinants of psychiatric disorders across the lifespan; 2) integrating genomics and neuroscience to unravel how genes affect brain structure and function; and 3) using “big data”, including electronic health records and genomics, to advance precision medicine.
Using genomic data, in collaboration with colleagues around the world, we have helped identify numerous genetic risk factors for psychiatric disorders and have demonstrated that these disorders have a surprising degree of shared genetics and biology.
We’ve also explored how genes effect brain structure and function and its relationship to mental illness by integrating genomics with neuroimaging and neurophysiologic phenotypes.
We have a deep interest in leveraging large scale data and computational methods to facilitate precision psychiatric approaches. This work includes using high dimensional data along with statistical and machine learning methods to identify risk and resilience factors as well as predictors of improved treatment response. Our hope is that this work will improve early detection, prevention, and patient care.
Dr. Jordan Smoller is the MGH Trustees Endowed Chair in Psychiatric Neuroscience, Professor of Psychiatry at Harvard Medical School and Professor in the Department of Epidemiology at the Harvard School of Public Health in Boston. He is Associate Chief for Research in the Massachusetts General Hospital (MGH) Department of Psychiatry and Director of both the Psychiatric and Neurodevelopmental Genetics Unit and the Precision Medicine Research Unit in the MGH Center for Genomic Medicine. Dr. Smoller is a Tepper Family MGH Research Scholar and also serves as Director of the Omics Unit of the MGH Division of Clinical Research and co-Director of the Partners HealthCare Biobank at MGH. He is an Associate Member of the Broad Institute and a Senior Scientist at the Broad’s Stanley Center for Psychiatric Research. He is also Vice President of the International Society of Psychiatric Genetics.
Individuals at high risk for schizophrenia may benefit from early intervention, but few validated risk predictors are available. Genetic profiling is one approach to risk stratification that has been extensively validated in research cohorts.
With information provided by volunteers across the United States, All of Us is developing a robust data platform to support a wide range of health studies.
Massachusetts General Hospital
Simches Research Building
185 Cambridge Street
Boston, MA 02114